Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial.

Authors : Azim HA, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG, Smith I, Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart-Gebhart M, de Azambuja E
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(36)
Pages : 4504-11

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial.

Authors : Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M
Year : 2013
Journal : Breast
Volume : 22(6)
Pages : 1060-5

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Authors : de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, Dhondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A
Year : 2013
Journal : Ann Oncol
Volume : 24(12)
Pages : 2985-9

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Authors : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Year : 2013
Journal : Lancet
Volume : 382(9897)
Pages : 1021-8

Planning cancer control in Latin America and the Caribbean.

Authors : Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, Louis JS, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G
Year : 2013
Journal : Lancet Oncol
Volume : 14(5)
Pages : 391-436

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Authors : Criscitiello C, Azim HA, Agbor-Tarh D, de Azambuja E, Piccart-Gebhart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT
Year : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1980-5

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.

Authors : Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M
Year : 2013
Journal : Breast Cancer Res. Treat.
Volume : 139(1)
Pages : 13-22

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

Authors : Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart M
Year : 2013
Journal : Cancer Treat Rev
Volume : 39(8)
Pages : 935-46

Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial.

Authors : Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber Rd, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(16)
Pages : 1954-60

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Authors : Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F
Year : 2012
Journal : Ann Oncol
Volume : 23 Suppl 7
Pages : vii155-66

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Authors : Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, de Azambuja E, Hainaut P, + collaborators (among others :, Larsimont D, Piccart-Gebhart M, Olivier M
Year : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pages : R70

Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer.

Authors : Pugliano L, de Azambuja E
Year : 2012
Journal : Onkologie
Volume : 35(9)
Pages : 476-8

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.

Authors : Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M
Year : 2012
Journal : J Oncol
Volume : 2012
Pages : 417673

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Authors : Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber Rd, Piccart-Gebhart M
Year : 2012
Journal : Lancet
Volume : 379(9816)
Pages : 633-40

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).

Authors : Azim HA, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M
Year : 2012
Journal : Breast Cancer Res. Treat.
Volume : 133(1)
Pages : 387-91

Dissecting the heterogeneity of triple-negative breast cancer.

Authors : Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M
Year : 2012
Journal : J. Clin. Oncol.
Volume : 30(15)
Pages : 1879-87

Targeted therapies in breast cancer: are heart and vessels also being targeted?

Authors : Criscitiello C, Metzger-Filho O, Saini KS, de Castro G, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart M
Year : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pages : 209

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.

Authors : Zardavas D, Bozovic-Spasojevic I, de Azambuja E
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(6)
Pages : 612-22

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.

Authors : Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, de Azambuja E, Piccart-Gebhart M
Year : 2012
Journal : Ann Oncol
Volume : 23(4)
Pages : 853-859

Chemoprevention for breast cancer.

Authors : Bozovic-Spasojevic I, de Azambuja E, McCaskill-Stevens W, Dinh P, Cardoso F
Year : 2012
Journal : Cancer Treat Rev
Volume : 38(5)
Pages : 329-339